Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2-Breast Cancer

Weiss Jennifer; Afghahi Anosheh; Shagisultanova Elena; Diamond Jennifer R.

首页> 外文期刊>Oncology >Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2-Breast Cancer

【24h】

Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2-Breast Cancer

机译：接近CDK4 / 6抑制剂在转移性HR +，HER2-乳腺癌中的使用

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Oncology》 |2018年第10期|共3页
作者
Weiss Jennifer; Afghahi Anosheh; Shagisultanova Elena; Diamond Jennifer R.;
展开▼
作者单位

Univ Colorado Dept Internal Med Anschutz Med Campus Aurora CO 80045 USA;

Univ Colorado Med Dept Oncol Anschutz Med Campus Aurora CO USA;

Univ Colorado Med Dept Oncol Anschutz Med Campus Aurora CO USA;

Univ Colorado Med DT Canc Program Anschutz Med Campus Aurora CO USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2-Breast Cancer [J] . Weiss Jennifer, Afghahi Anosheh, Shagisultanova Elena, Oncology . 2018,第10期

机译：接近CDK4 / 6抑制剂在转移性HR +，HER2-乳腺癌中的使用
2. Therapy of advanced HR+, HER2-Breast Cancer Live professionally longer with CDK4/6 Inhibitor [J] . Ruedesheim Sabine M. Breast care . 2021,第3期

机译：治疗高级HR +，HER2-乳腺癌患有CDK4 / 6抑制剂的专业更长
3. A phase I/IIb study of palbociclib (PALBO) plus everolimus (EVE) and exemestane (EXE) in hormone-receptor positive (HR+)/HER2-metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i): Results of the phase II study [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：在CDK4 / 6抑制剂的进展后，在激素受体阳性（HR +）/ Her2-转移性乳腺癌（MBC）中的帕尔巴昔米菌（Palbo）和EveSeTane（Eve）和exemestane（EXE）研究（CDK4 / 6i ）：II期研究的结果
4. Classification of Metastatic Breast Cancer Cell using Deep Learning Approach [C] . Seohyun Lee, Hyuno Kim, Hideo Higuchi, International Conference on Artificial Intelligence in Information and Communication . 2021

机译：深层学习方法转移乳腺癌细胞分类
5. Identification of Genomic Predictors of Response to the CDK4/6 Inhibitor Palbociclib using the UCLATORL Panel of Human Cancer Cell Lines [D] . Conklin, Dylan Francis 2013

机译：使用人类癌细胞系UCLATORL小组鉴定对CDK4 / 6抑制剂Palbociclib应答的基因组预测因子
6. MONARCH 1 a phase 2 study of abemaciclib a CDK4 and CDK6 inhibitor as a single agent in patients with refractory HR+/HER2− metastatic breast cancer [O] . Maura N. Dickler, Sara M. Tolaney, Hope S. Rugo, -1

机译：MONARCH 1CDB4和CDK6抑制剂abemaciclib作为单一药物的2期研究用于难治性HR + / HER2-转移性乳腺癌患者
7. CDK4/6 inhibitors in HR+/HER2- advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies [O] . Nadia Harbeck, Meaghan Bartlett, Dean Spurden, 2021

机译：HR + / HER2-先进/转移性乳腺癌中CDK4 / 6抑制剂：对现实世界的证据研究进行了系统的文献综述
8. Novel Differentiation Therapy Approach to Reduce the Metastatic Potential of Basal, Highly Metastatic, Triple-Negative Breast Cancers. [R] . Chu, I. 2012

机译：新型分化治疗方法降低基底，高转移性，三阴性乳腺癌的转移潜能。

Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2-Breast Cancer

著录项

引文网络

相似文献

相关主题

期刊订阅